7824 â 51 Avenue NW
Edmonton, AB T6E 6W2
Full Time Employees:
|Mr. Gilles R. Gagnon M.B.A., M.Sc., MBA, ICD.D||CEO, Pres & Director||480k||N/A||1954|
|Ms. Stacy Prefontaine CPA, CA||CFO & Corp. Sec.||195.25k||N/A||N/A|
|Dr. Bernhard Seifried||Sr. Director of Research & Technology||N/A||N/A||N/A|
Ceapro Inc., a biotechnology company, engages in the development and commercialization of active ingredients in the United States, Germany, China, Canada, and internationally. It operates in two segments, The Active Ingredient Product Technology Industry and The Cosmeceutical Industry. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company's products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, such as Pressurized Gas eXpanded drying technology; and technologies to enhance the content of avenanthramides. The company has a collaboration with the McMaster University to develop inhalable therapeutic for COVID-19; a research project with the University of Alberta to expand the utilization of the PGX technology and generate ingredients targeting applications in functional food, dietary supplement, personal care, and pharmaceuticals; a research collaboration with Montreal Heart Institute for clinical study evaluating avenanthramide; and a research collaboration with Angiogenesis Foundation. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada.
Ceapro Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.